MORE►
CerSci Therapeutics
Lucas Rodriguez, CerSci [Photo: Skyler Fike]
Dallas-based Biotech CerSci Acquired by ACADIA Pharmaceutical in $52.5M Deal
by Quincy Preston | Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
by Lance Murray |
Feb 26, 2020
Using innovative new technologies and targeted therapies, the Dallas biotech startup aims to help patients with cancer, give them hope, and prolong their lives.
MORE►
by Alex Edwards |
Apr 1, 2019
CerSci's focus is on alleviating human suffering and rescuing society from the ongoing opioid crisis via a pain drug that does not affect the central nervous system.
MORE►
by Dallas Innovates | Staff Report |
Jan 24, 2018
Funding rounds brought millions in capital from investors for North Texas startups.
MORE►
